Background
Pulmonary hypertension has been associated with early allograft dysfunction and increased mortality following renal transplantation however this relationship has not been extensively studied.
Methods
We performed a retrospective cohort study of adult patients who underwent their first renal transplantation from 2003–2009 and had pre-transplantation echocardiograms. Pulmonary hypertension was defined as a right ventricular systolic pressure ≥ 40 mmHg in the absence of left-sided valvular disease and/or left ventricular ejection fraction ≤ 50%. The relationship between pulmonary hypertension and death-censored allograft failure (hemodialysis dependence or re-transplantation) and serum creatinine was assessed using Cox hazard regression and generalized mixed models. Eighty-two of 205 (40%) patients met inclusion criteria.
Results
The presence of pulmonary hypertension was associated with a 3.00 fold increase in the risk of death-censored allograft failure (95% confidence interval 1.20 – 7.32, p=0.02). Failure rates were 19% at 24 months and 51% at 96 months for those with pulmonary hypertension versus 7% at 24 months and 20% at 86 months for those without pulmonary hypertension (p=0.01). Among those without graft failure, there was an increase in creatinine levels after transplant (p=0.01). Effect estimates were unchanged by adjustment for multiple covariates and when pulmonary hypertension was defined as a right ventricular systolic pressure ≥ 36 mmHg.
Conclusions
Pulmonary hypertension prior to renal transplantation carries a 3.00-fold increased risk of death-censored allograft failure. The relationship between the pulmonary circulation and renal allograft failure warrants further study.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.